Chinook Therapeutics welcomes Dr. Mahesh Krishnan to its Board of Directors

– USA, WA – Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, today announced the appointment of Dr. Mahesh Krishnan (M.D., M.P.H., FASN) to its Board of Directors, bringing more than 20 years of practicing nephrology and industry experience to Chinook.

About Dr. Mahesh Krishnan

Dr. Krishnan currently serves as group VP of research and development at DaVita Inc. In his role, Dr. Krishnan is responsible for strategic partnerships in technology and research and development at DaVita, as well as medical policy in Washington, D.C. Previously, Dr. Krishnan served as DaVita’s first international CMO in which he oversaw its growth in 10 countries. Dr. Krishnan is an expert on quality measurement and data systems in dialysis and the past guided the policy and implementation of the ESRD bundle, one of Medicare’s first value-based purchasing programs. He has a passion for service design to improve the quality, efficiency, and effectiveness of healthcare delivery. Before joining DaVita, Dr. Krishnan was at Amgen, where he served as medical director for Epogen®, head of global health economics and outcomes research for nephrology, and medical policy lead for all domestic Amgen products. Before Amgen, Dr. Krishnan was a practicing nephrologist in Northern Virginia. He has served on editorial boards, has written two books, and has more than 60 peer-reviewed publications. Dr. Krishnan earned his medical degree from The Jefferson Medical College at Thomas Jefferson University.

“I am excited to join Chinook’s board to help advance its mission of developing precision medicines for kidney diseases,” said Dr. Krishnan. “The company is a leader in the kidney disease space with emerging best-in-class programs and a strong balance sheet, and I look forward to collaborating with the board and leadership team on the company’s next phase of growth and development.”

He holds an M.P.H. from Johns Hopkins University and an M.B.A. in medical services management at the Johns Hopkins Carey School of Business.

About Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single-cell RNA sequencing, human-derived organoids, and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team